ArticleFrontiers in oncology2025
Clinical characteristics and analysis of cerebrospinal fluid biochemical, tumor markers and cytologic indices in 209 patients with meningeal carcinomatosis: a cross-sectional study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the clinical characteristics and cerebrospinal fluid (CSF) biochemical indexes, tumor markers (TM) and cytomorphological indexes of patients with meningeal carcinomatosis (MC), and to explore the clinical application value of the above indexes. Methods: Retrospectively included 209 patients with MC in 2021-2023 into the study and collected their clinical information and laboratory data, compared the differences in indicators and analyzed the cytomorphological features and dynamic changes. Results: (i) The primary foci of MC patients were mostly lung cancer (86.6%), and the clinical manifestations did not change according to the tumor of the primary foci. The main manifestations were headache (65.55%) and meningeal enhancement (67.20%); (ii)Most MC patients (96.17%) had abnormal CSF biochemical indices, with some variations among primary foci; (iii) CYFRA21-1 level in CSF of MC patients was significantly higher than that in serum (P<0.05); (iv) The first detection rate of atypical cells in CSF of MC patients in our center was 95.22%, and the morphological characteristics were correlated with the primary foci; (v)Dynamic monitoring showed that the level of TM in CSF was consistent with the changes in the proportion of atypical cells in CSF, which could suggest fluctuations in the disease. Conclusion: In this study, it is clear that the clinical characteristics of MC patients and the CSF indicators have specific distribution patterns, and the combined analysis of CSF biochemical indicators, TMr levels and cytomorphology can provide a key basis for the diagnosis of MC, the indication of primary foci and the monitoring of the disease, and the large-scale single-center data provide a reliable support for its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.